Brief: MoonLake Immunotherapeutics Says Expected Cash Runway Extended To End Of 2024
12/05/2023 13:55
May 12 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES
A
BUSINESS UPDATE
* EXPECTED CASH RUNWAY EXTENDED TO END OF 2024
* AS OF MARCH 31, HELD CASH, CASH EQUIVALENTS AND SHORT-TERM
MARKETABLE DEBT SECURITIES OF $63.1 MILLION
* QTRLY BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO
CONTROLLING INTERESTS SHAREHOLDERS $0.23
* Q1 EARNINGS PER SHARE VIEW $-0.31 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4B99Zg
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial